New York, USA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Propulsion of Hypertriglyceridemia Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight
The prevalence of hypertriglyceridemia is increasing due to higher consumption of unhealthy foods and lifestyles, which is projected to expand the scope of the global hypertriglyceridemia market. Major market players are investing in the development of novel drugs and launching these products in the market, which in turn is projected to significantly increase the market growth and create productive growth opportunities in the global hypertriglyceridemia market. The companies developing the potential therapies in the late stage of development include Mochida Pharmaceutical, Ionis Pharmaceuticals, 89bio, and several others.
DelveInsight’s 'Hypertriglyceridemia Pipeline Insight 2023' report provides comprehensive global coverage of pipeline Hypertriglyceridemia therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Hypertriglyceridemia pipeline domain.
Key Takeaways from the Hypertriglyceridemia Pipeline Report
- DelveInsight’s hypertriglyceridemia pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for hypertriglyceridemia treatment.
- Key hypertriglyceridemia companies such as Arrowhead Pharmaceuticals, Mochida Pharmaceutical, Ionis Pharmaceuticals, 89bio, Regeneron Pharmaceuticals, Staten Biotechnology BV, NorthSea Therapeutics B.V., Rivus Pharmaceuticals, Viking Therapeutics, Matinas BioPharma, Eli Lilly and Company, GeneCradle Therapeutics, and others are evaluating new hypertriglyceridemia drugs to improve the treatment landscape.
- Promising hypertriglyceridemia pipeline therapies such as ARO-APOC3, MND-21, IONIS-APOCIII-LRx, Pegozafermin, Evinacumab, STT-5058, NST-1024, HU 6, MAT-9001, VK 1430, LY3875383, GC 304, and others are under different phases of hypertriglyceridemia clinical trials.
- In June 2023, 89bio announced that the previously reported positive data from the Phase 2 ENTRIGUE trial of pegozafermin in patients with severe hypertriglyceridemia (SHTG) were published online in Nature Medicine. As previously announced, ENTRIGUE met its primary endpoint of demonstrating statistically significant reductions in median triglycerides (TGs) from baseline in pegozafermin-treated patients across all dose groups compared to placebo after eight weeks of treatment.
- In May 2023, 89bio, a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the initiation of ENTRUST, a Phase 3 trial evaluating the efficacy, safety, and tolerability of pegozafermin in patients with severe hypertriglyceridemia (SHTG).
- In November 2022, OrsoBio, a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, announced its acquisition of assets relating to the Liver X Receptor (LXR) inverse agonist program from Phenex Pharmaceuticals, including lead candidate TLC-2716 and associated intellectual property. The unique pharmacology of TLC-2716, namely hepatic and intestinal restriction, mitigates potential impact on peripheral reverse cholesterol transport, and supports its development for the treatment of patients with severe hypertriglyceridemia, familial hypercholesterolemia, and nonalcoholic steatohepatitis (NASH).
- In October 2022, Arrowhead Pharmaceuticals announced the presentation of interim clinical data from the ongoing SHASTA-2 Phase 2 study of ARO-APOC3 in patients with severe hypertriglyceridemia and the ongoing ARCHES-2 Phase 2 clinical study of ARO-ANG3 in patients with mixed dyslipidemia, in late-breaking oral presentations at the American Heart Association (AHA) Scientific Sessions 2022, being held in Chicago.
- In April 2022, Kyttaro announced that it had entered into an agreement for the worldwide exclusive license of an anti-angiopoietin-like (ANGPTL) 3/8 monoclonal antibody program developed by Eli Lilly and Company (Lilly) for potential treatment of atherosclerotic cardiovascular disease (ASCVD) and linked dyslipidemias: hypertriglyceridemia and hypercholesterolemia.
Request a sample and discover the recent advances in hypertriglyceridemia treatment drugs @ Hypertriglyceridemia Pipeline Report
The hypertriglyceridemia pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage hypertriglyceridemia drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the hypertriglyceridemia clinical trial landscape.
Hypertriglyceridemia Overview
Hypertriglyceridemia is a medical condition characterized by elevated levels of triglycerides in the blood. Triglycerides are a type of fat found in the bloodstream, and their levels are influenced by diet, genetics, and overall metabolic health. High triglyceride levels are often associated with an increased risk of cardiovascular diseases. Symptoms of hypertriglyceridemia may vary, but they are often absent or subtle. In some cases, individuals may experience symptoms such as abdominal pain, pancreatitis, or eruptive xanthomas. However, more commonly, hypertriglyceridemia is diagnosed incidentally during routine blood tests.
The diagnosis of hypertriglyceridemia is made through a blood test called a lipid panel or lipid profile. This test measures the levels of various lipids in the blood, including triglycerides. Typically, a fasting sample is required to obtain accurate results. The treatment of hypertriglyceridemia aims to reduce triglyceride levels and manage associated risk factors. Lifestyle modifications play a crucial role and include adopting a heart-healthy diet low in saturated fats and sugars, increasing physical activity, losing weight if necessary, and avoiding excessive alcohol consumption.
Find out more about hypertriglyceridemia treatment drugs @ Drugs for Hypertriglyceridemia Treatment
A snapshot of the Hypertriglyceridemia Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| Olezarsen | Ionis Pharmaceuticals | Phase III | Apolipoprotein C III expression inhibitors; RNA interference | Subcutaneous |
| MND-21 | Mochida Pharmaceutical | Phase III | Diacylglycerol O acyltransferase inhibitors; Phospholipase A2 inhibitors; Platelet aggregation inhibitors; Triglyceride modulators | Oral |
| Pegozafermin | 89bio | Phase III | Fibroblast growth factor 21 agonists | Subcutaneous |
| ARO-APOC3 | Arrowhead Pharmaceuticals | Phase II | Apolipoprotein C-III inhibitors; RNA interference | Subcutaneous |
| Evinacumab | Regeneron Pharmaceuticals | Phase II | ANGPTL3 protein inhibitors | Intravenous |
| LY3875383 | Eli Lilly and Company | Phase I | NA | Subcutaneous |
Learn more about the emerging hypertriglyceridemia pipeline therapies @ Hypertriglyceridemia Clinical Trials
Hypertriglyceridemia Therapeutics Assessment
The hypertriglyceridemia pipeline report proffers an integral view of the hypertriglyceridemia emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Hypertriglyceridemia Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
- Therapeutics Assessment By Molecule Type: Monoclonal Antibody, Peptides, Polymer, Small molecule, Gene therapy
- Therapeutics Assessment By Mechanism of Action: Apolipoprotein C-III inhibitors, RNA interference, Diacylglycerol O acyltransferase inhibitors, Phospholipase A2 inhibitors, Platelet aggregation inhibitors, Triglyceride modulators, Fibroblast growth factor 21 agonists, ANGPTL3 protein inhibitors
- Key Hypertriglyceridemia Companies: Arrowhead Pharmaceuticals, Mochida Pharmaceutical, Ionis Pharmaceuticals, 89bio, Regeneron Pharmaceuticals, Staten Biotechnology BV, NorthSea Therapeutics B.V., Rivus Pharmaceuticals, Viking Therapeutics, Matinas BioPharma, Eli Lilly and Company, GeneCradle Therapeutics, and others
- Key Hypertriglyceridemia Pipeline Therapies: ARO-APOC3, MND-21, IONIS-APOCIII-LRx, Pegozafermin, Evinacumab, STT-5058, NST-1024, HU 6, MAT-9001, VK 1430, LY3875383, GC 304, and others
Dive deep into rich insights for new drugs for hypertriglyceridemia treatment, visit @ Hypertriglyceridemia Drugs
Table of Contents
| 1. | Hypertriglyceridemia Pipeline Report Introduction |
| 2. | Hypertriglyceridemia Pipeline Report Executive Summary |
| 3. | Hypertriglyceridemia Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Hypertriglyceridemia Clinical Trial Therapeutics |
| 6. | Hypertriglyceridemia Pipeline: Late-Stage Products (Pre-registration) |
| 7. | Hypertriglyceridemia Pipeline: Late-Stage Products (Phase III) |
| 8. | Hypertriglyceridemia Pipeline: Mid-Stage Products (Phase II) |
| 9. | Hypertriglyceridemia Pipeline: Early-Stage Products (Phase I) |
| 10. | Hypertriglyceridemia Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Hypertriglyceridemia Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Hypertriglyceridemia Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the hypertriglyceridemia pipeline therapeutics, reach out @ Hypertriglyceridemia Treatment Drugs
Related Reports
Hypertriglyceridemia Epidemiology
Hypertriglyceridemia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted hypertriglyceridemia epidemiology in the 7MM.
Hypertriglyceridemia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hypertriglyceridemia companies including Arrowhead Pharmaceuticals, Mochida Pharmaceutical, Ionis Pharmaceuticals, 89bio, Regeneron Pharmaceuticals, Staten Biotechnology BV, NorthSea Therapeutics B.V., among others.
Severe Hypertriglyceridemia Pipeline
Severe Hypertriglyceridemia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key severe hypertriglyceridemia companies, including Arrowhead Pharmaceuticals, Ionis Pharmaceuticals, Inc., 89bio, Inc., Regeneron Pharmaceuticals, Kowa Research Institute, Inc., Mochida Pharmaceutical, Acasti Pharma Inc., NorthSea Therapeutics, Matinas BioPharma, among others.
Severe Hypertriglyceridemia Market
Severe Hypertriglyceridemia Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key severe hypertriglyceridemia companies including Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., Afimmune Pharmaceutical, NorthSea Therapeutics B.V., Amryt Pharma, among others.
Severe Hypertriglyceridemia Epidemiology
Severe Hypertriglyceridemia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted severe hypertriglyceridemia epidemiology in the 7MM.
Other Trending Reports
Actinic Keratosis Market | Acute Coronary Syndrome Market | Acute Pulmonary Embolism Market | Alpha Antitrypsin Market | Apraxia Market | Bile Duct Neoplasm Market | Choroidal Neovascularization Market | Eczema Market | Familial Primary Pulmonary Hypertension Market | Fibrocystic Breast Condition Market | Meningioma Market | Neuroblastoma Market | Opioid Induced Constipation Market | Progressive Multifocal Leukoencephalopathy Market | Rhino Conjunctivitis Market | Ventilator Market | Angioedema Market | Hereditary Angioedema Market | Allergic Conjunctivitis Market | Blood Gas And Electrolyte Analyzers Market | Capnography Device Market | Cervical Intraepithelial Neoplasia Market | Food Allergy Market | Foot And Ankle Devices Market | Intracranial Pressure Monitoring Devices Market | Neurostimulation Devices Market | Neurovascular Devices Market | Osteoarthritis Market | Vascular Access Devices Market | Pruritus Market
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
